Reversing LRP5-Dependent Osteoporosis and SOST Deficiency–Induced Sclerosing Bone Disorders by Altering WNT Signaling Activity

In conclusion, our data highlight the potential for novel drug targeting approaches in rare skeletal disorders ranging from severe skeletal fragility to sclerosing bone overgrowth through selective modulation of canonical WNT signaling.

These approaches should also be beneficial in the context of other medical conditions with much less severe phenotypes, such as postmenopausal osteoporosis, given the crucial role of this potent bone anabolic pathway for skeletal homeostasis